A Phase Ii Study on Combination of Axitinib and Transarterial Chemoembolization (Tace) for Treatment of Inoperable Hepatocellular Carcinoma (Hcc)

Chan, Stephen L.; Yeo, Winnie; Mo, Frankie; Li, L.; Lee, K.; Hui, P. W.; Ma, Brigette; Mok, T.; Chan, Anthony T.C.; Lai, Paul Bo San; Yu, Simon Chun‐Ho

doi:10.1093/annonc/mdu334.115

Cited by 1 publication

(1 citation statement)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Cabozantinib demonstrated favorable improvement of survival, while Regorafenib proved beneficial as well, despite the former dose of sorafenib, without the aggravation of the side effects. There are multiple other pharmaceutical molecules that are still in the phase II studies and showed favorable results for HCC management, such as axitinib, a tyrosine kinase inhibitor (TKI), combined with transarterial chemoembolization (TACE), which demonstrated notable effectiveness for advanced HCC [ 28 ], decitabine, which was found beneficial in low doses, without remarkable toxicity [ 29 ] and nintedanib that showed effects alike sorafenib [ 30 ]. The molecular targets of the above-mentioned drugs and the biochemical pathways for their effect are shown in Figure 1 .…”

Section: Immunotherapy Strategies For Hccmentioning

confidence: 99%

An Insight into the Novel Immunotherapy and Targeted Therapeutic Strategies for Hepatocellular Carcinoma and Cholangiocarcinoma

Trifylli

Koustas

Papadopoulos³

et al. 2022

Life

View full text Add to dashboard Cite

Hepatocellular carcinoma (HCC) and cholangiocarcinoma (CCA) constitute highly malignant forms of primary liver cancers. Hepatocellular and bile duct carcinogenesis is a multiplex process, caused by various genetic and epigenetic alterations, the influence of environmental factors, as well as the implication of the gut microbiome, which was undervalued in the previous years. The molecular and immunological analysis of the above malignancies, as well as the identification of the crucial role of intestinal microbiota for hepatic and biliary pathogenesis, opened the horizon for novel therapeutic strategies, such as immunotherapy, and enhanced the overall survival of cancer patients. Some of the immunotherapy strategies that are either clinically applied or under pre-clinical studies include monoclonal antibodies, immune checkpoint blockade, cancer vaccines, as well as the utilization of oncolytic viral vectors and Chimeric antigen, receptor-engineered T (CAR-T) cell therapy. In this current review, we will shed light on the recent therapeutic modalities for the above primary liver cancers, as well as on the methods for the enhancement and optimization of anti-tumor immunity.

show abstract

Section: Immunotherapy Strategies For Hccmentioning

confidence: 99%